[go: up one dir, main page]

EA200600896A1 - Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря - Google Patents

Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря

Info

Publication number
EA200600896A1
EA200600896A1 EA200600896A EA200600896A EA200600896A1 EA 200600896 A1 EA200600896 A1 EA 200600896A1 EA 200600896 A EA200600896 A EA 200600896A EA 200600896 A EA200600896 A EA 200600896A EA 200600896 A1 EA200600896 A1 EA 200600896A1
Authority
EA
Eurasian Patent Office
Prior art keywords
urinary bladder
irritation
treating
overly active
treating urinary
Prior art date
Application number
EA200600896A
Other languages
English (en)
Other versions
EA012409B1 (ru
Inventor
Крэйг П. Смит
Мишель П. Рэтбоун
Маргарет Петти
Дэвид Рэмп
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of EA200600896A1 publication Critical patent/EA200600896A1/ru
Publication of EA012409B1 publication Critical patent/EA012409B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к N-(пиридинил)-1H-индол-1-аминам формулы I, которые имеют уникальную комбинацию блокирующих свойств как в отношении калиевых, так и в отношении натриевых каналов. Указанные соединения полезны для лечения раздражения и дисфункции мочевого пузыря.
EA200600896A 2001-02-15 2002-02-14 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря EA012409B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions

Publications (2)

Publication Number Publication Date
EA200600896A1 true EA200600896A1 (ru) 2006-08-25
EA012409B1 EA012409B1 (ru) 2009-10-30

Family

ID=23024747

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600896A EA012409B1 (ru) 2001-02-15 2002-02-14 Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
EA200300882A EA011319B1 (ru) 2001-02-15 2002-02-14 Способ лечения демиелинизирующих заболеваний или состояний

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200300882A EA011319B1 (ru) 2001-02-15 2002-02-14 Способ лечения демиелинизирующих заболеваний или состояний

Country Status (39)

Country Link
US (10) US6967210B2 (ru)
EP (1) EP1368031A2 (ru)
JP (3) JP2004518711A (ru)
KR (3) KR20090005254A (ru)
CN (2) CN1529598A (ru)
AP (1) AP1749A (ru)
AR (1) AR035750A1 (ru)
AU (3) AU2002247200B9 (ru)
BR (1) BR0207272A (ru)
CA (1) CA2438712A1 (ru)
CO (1) CO5390085A1 (ru)
CR (1) CR7023A (ru)
CZ (1) CZ20032172A3 (ru)
EA (2) EA012409B1 (ru)
EC (1) ECSP024218A (ru)
EE (1) EE200300363A (ru)
GB (1) GB0119435D0 (ru)
HK (1) HK1080361B (ru)
HR (1) HRP20030652A2 (ru)
HU (1) HUP0303203A3 (ru)
IL (2) IL157341A0 (ru)
MA (1) MA26152A1 (ru)
ME (1) MEP21208A (ru)
MX (1) MXPA03006110A (ru)
MY (1) MY157745A (ru)
NO (1) NO20033622L (ru)
NZ (4) NZ556697A (ru)
OA (1) OA12549A (ru)
PA (1) PA8540101A1 (ru)
PE (1) PE20040175A1 (ru)
PL (1) PL363638A1 (ru)
SG (1) SG134170A1 (ru)
SK (1) SK10392003A3 (ru)
TR (4) TR200800693T2 (ru)
TW (1) TWI325319B (ru)
UA (2) UA80394C2 (ru)
WO (1) WO2002064126A2 (ru)
YU (1) YU62903A (ru)
ZA (1) ZA200306124B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
EP3727587A4 (en) 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
EP0415103B1 (en) * 1989-08-02 1995-02-01 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
WO1999038873A1 (en) * 1998-01-29 1999-08-05 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
US6544976B1 (en) * 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
TR200800693T2 (tr) 2008-07-21
NZ527011A (en) 2005-07-29
MXPA03006110A (es) 2005-07-01
HK1080361A1 (zh) 2006-04-28
CN1529598A (zh) 2004-09-15
CO5390085A1 (es) 2004-04-30
HK1080361B (zh) 2009-10-30
IL157341A (en) 2010-11-30
US20090270458A1 (en) 2009-10-29
MEP21208A (en) 2010-06-10
CN1679564A (zh) 2005-10-12
US7230015B2 (en) 2007-06-12
US20090209595A1 (en) 2009-08-20
JP2004518711A (ja) 2004-06-24
GB0119435D0 (en) 2001-10-03
EE200300363A (et) 2003-10-15
EA011319B1 (ru) 2009-02-27
ZA200306124B (en) 2004-11-08
CZ20032172A3 (cs) 2004-01-14
KR100951540B1 (ko) 2010-04-09
EA012409B1 (ru) 2009-10-30
US20040157889A1 (en) 2004-08-12
US20050234105A1 (en) 2005-10-20
US20090281147A1 (en) 2009-11-12
UA88773C2 (ru) 2009-11-25
US7534803B2 (en) 2009-05-19
HUP0303203A3 (en) 2007-11-28
US20050159456A1 (en) 2005-07-21
KR20040014459A (ko) 2004-02-14
AU2009238332A1 (en) 2009-12-10
BR0207272A (pt) 2004-02-10
KR20090005255A (ko) 2009-01-12
TR200301330T2 (tr) 2004-12-21
IL157341A0 (en) 2004-02-19
NZ539159A (en) 2006-11-30
US6967210B2 (en) 2005-11-22
PA8540101A1 (es) 2003-09-05
TR200800691T2 (tr) 2008-03-21
US20060025452A1 (en) 2006-02-02
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
UA80394C2 (en) 2007-09-25
KR20090005254A (ko) 2009-01-12
PL363638A1 (en) 2004-11-29
HRP20030652A2 (en) 2005-06-30
NZ556697A (en) 2009-01-31
PE20040175A1 (es) 2004-03-29
NO20033622D0 (no) 2003-08-14
US20090209594A1 (en) 2009-08-20
AP2003002834A0 (en) 2003-09-30
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
NZ544720A (en) 2007-08-31
AP1749A (en) 2007-06-13
YU62903A (sh) 2006-05-25
US7179821B2 (en) 2007-02-20
AR035750A1 (es) 2004-07-07
AU2008201179A1 (en) 2008-04-03
CR7023A (es) 2003-11-17
KR100951542B1 (ko) 2010-04-09
NO20033622L (no) 2003-10-06
AU2002247200B9 (en) 2008-07-10
OA12549A (en) 2006-06-05
ECSP024218A (es) 2003-09-24
WO2002064126A3 (en) 2003-02-20
JP2009185045A (ja) 2009-08-20
HUP0303203A2 (hu) 2003-12-29
EA200300882A1 (ru) 2003-12-25
WO2002064126A2 (en) 2002-08-22
EP1368031A2 (en) 2003-12-10
AU2002247200B2 (en) 2007-12-13
US20030105150A1 (en) 2003-06-05
CA2438712A1 (en) 2002-08-22
MA26152A1 (fr) 2004-07-01
CN100522164C (zh) 2009-08-05
US20040157888A1 (en) 2004-08-12
AU2008201179B2 (en) 2009-08-20
JP2010120958A (ja) 2010-06-03
SG134170A1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
EA200600896A1 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DE60112974D1 (en) Carbolinderivate
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR0314059A (pt) Compostos heterocìclicos
MY140767A (en) Compounds, methods and compositions
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
AU3831301A (en) Method for treating ocular pain
CY1108808T1 (el) Ενωσεις μοτιλιδης
NO20033220L (no) Inhibitorer for cruzipain og andre cysteinproteaser
DE60216233D1 (en) Carbolinderivate
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
NO20054494L (no) Peptidvektorer
WO2005060693A3 (en) 9-desoxoerythromycin compounds as prokinetic agents
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
NO20015892D0 (no) Inhibitorer av metallproteinaser
MY136367A (en) Treatment of cognitive failure
NO20032406D0 (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
WO2003028652A3 (en) Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
ATE348803T1 (de) Tryptase-inhibitoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU